Response and resistance to BET bromodomain inhibitors in triple negative breast cancer

Triple negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy(1-3). BET bromodomain inhibitors, which have shown efficacy in several models of cancer(4-6), have not been evaluated in TNBC. These inhibitors displace BET bromodomain pr...

Full description

Saved in:
Bibliographic Details
Published in:Nature
Main Authors: Shu, Shaokun, Lin, Charles Y., He, Housheng Hansen, Witwicki, Robert M., Tabassum, Doris P., Roberts, Justin M., Janiszewska, Michalina, Huh, Sung Jin, Liang, Yi, Ryan, Jeremy, Doherty, Ernest, Mohammed, Hisham, Guo, Hao, Stover, Daniel G., Ekram, Muhammad B., Brown, Jonathan, D'Santos, Clive, Krop, Ian E., Dillon, Deborah, McKeown, Michael, Ott, Christopher, Qi, Jun, Ni, Min, Rao, Prakash K., Duarte, Melissa, Wu, Shwu-Yuan, Chiang, Cheng-Ming, Anders, Lars, Young, Richard A., Winer, Eric, Letai, Antony, Barry, William T., Carroll, Jason S., Long, Henry, Brown, Myles, Liu, X. Shirley, Meyer, Clifford A., Bradner, James E., Polyak, Kornelia
Format: Artigo
Language:Inglês
Published: 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4854653/
https://ncbi.nlm.nih.gov/pubmed/26735014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature16508
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items